SYSTEMIC SCLERODERMA TREATMENT MARKET ANALYSIS

Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4641
Pages :164
Formats :
Excel and PDF
Industry : Pharmaceutical

Systemic Scleroderma Treatment MarketSize and Trends

The global systemic scleroderma treatment market is estimated to be valued at US$ 1,520.1 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Systemic Scleroderma Treatment Market Report Coverage

Figure 1. Global Systemic Scleroderma Treatment Market Share (%), By Region, 2021

The increasing prevalence of scleroderma is expected to drive the growth of the global systemic scleroderma treatment market over the forecast period.

For instance, according to an article published by the Journal of Managed Care & Specialty Pharmacy in December 2020, the prevalence of systemic scleroderma increased from 7.8 per 100,000 in 2011 to 24.3 per 100,000 people in 2016 in the U.S and is expected to further increase in the near future.

The increasing research and development activities for the development of novel therapeutics for the treatment of scleroderma is expected to drive the market growth over the forecast period.

For instance, according to study results published in the Journal of Rheumatology in March 2017, Imatinib Mesylate (Gleevec), an oral chemotherapy medication showed positive results to be used in the treatment of diffuse cutaneous systemic sclerosis. Imatinib Mesylate (Gleevec) is manufactured by Novartis Pharmaceuticals, a Switzerland based pharmaceutical company.

Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of scleroderma, which is expected to drive growth of the global systemic scleroderma treatment market over the forecast period.

For instance, in September 2019, Boehringer Ingelheim International GmbH, a Germany based pharmaceutical company received the U.S. Food and Drug Administration Approval for Ofev (nintedanib), a drug which is to be used to treat patients with systemic sclerosis associated interstitial lung disease.

Figure 2. Global Systemic Scleroderma Treatment Market Value (US$ Mn), By Drug Class, 2021